Syra Health (SYRA) investors approve director slate, auditor and expand equity plan
Rhea-AI Filing Summary
Syra Health Corp. held its Annual Meeting of Stockholders on July 23, 2026, with 13,664,105 shares of common stock represented, including 350,000 Class B shares carrying 16.5 votes per share, constituting a quorum.
Stockholders elected all five director nominees to serve until the 2027 annual meeting. They also ratified M&K CPAs, PLLC as independent registered public accounting firm for the fiscal year ended December 31, 2026, with 12,133,305 votes in favor. In addition, stockholders approved an amendment to the Company's 2022 Omnibus Equity Incentive Plan, increasing the number of Class A shares available for issuance to 4,100,000, with 8,548,265 votes for and 2,691,142 against.
Positive
- None.
Negative
- None.
Filing Explained
The July 23 vote approved expanding the 2022 Omnibus Equity Incentive Plan’s Class A share capacity to 4,100,000, creating room for future plan issuances; the filing does not report that these shares were issued or that existing holders were diluted.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented at meeting: 13,664,105 shares
Class B voting power: 350,000 shares; 16.5 votes per share
Auditor ratification votes for: 12,133,305 votes
+2 more
5 metrics
Shares represented at meeting
13,664,105 shares
Shares of common stock represented in person or by proxy at the July 23, 2026 annual meeting
Class B voting power
350,000 shares; 16.5 votes per share
Class B common stock included in meeting quorum, each share carrying 16.5 votes
Auditor ratification votes for
12,133,305 votes
Votes in favor of ratifying M&K CPAs, PLLC as auditor for fiscal year ended December 31, 2026
Equity plan pool after amendment
4,100,000 Class A shares
Number of Class A shares available for issuance under the 2022 Omnibus Equity Incentive Plan after amendment
Equity plan amendment votes for
8,548,265 votes
Votes in favor of amending the 2022 Omnibus Equity Incentive Plan
Key Terms
Broker Non Vote, 2022 Omnibus Equity Incentive Plan, independent registered public accounting firm
3 terms
Broker Non Vote financial
"For | Against | Abstain | Broker Non Vote 8,548,265 | 2,691,142 | 452 | 2,424,246"
When a broker holds shares for a client but does not have the client’s instructions to vote on a particular corporate matter, the broker often cannot cast a ballot; this is called a broker non-vote. It matters to investors because those uncast votes can change whether proposals pass, especially on important governance or merger issues, so active voting by investors can directly influence company decisions like a missing voice in a group vote.
2022 Omnibus Equity Incentive Plan financial
"The amendment to the Company’s 2022 Omnibus Equity Incentive Plan increasing the number"
independent registered public accounting firm financial
"The appointment of M&K CPAs, PLLC, as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Syra Health (SYRA) stockholders vote on at the July 23, 2026 annual meeting?
Stockholders elected five directors, ratified M&K CPAs, PLLC as auditor for 2026, and approved an amendment to the 2022 Omnibus Equity Incentive Plan increasing available Class A shares to 4,100,000.
Were all Syra Health (SYRA) director nominees elected in 2026?
Yes. All five director nominees received sufficient votes for election, with each nominee, including Priya Prasad and Dr. Vijayapal R. Reddy, receiving over 9.4 million votes for and no votes recorded against.
Did Syra Health (SYRA) stockholders approve the 2022 Omnibus Equity Incentive Plan amendment?
Yes. Stockholders approved the amendment to the 2022 Omnibus Equity Incentive Plan, increasing Class A shares available for issuance to 4,100,000, with 8,548,265 votes for and 2,691,142 votes against plus broker non-votes.
Was M&K CPAs, PLLC ratified as Syra Health (SYRA) auditor for 2026?
Yes. Stockholders ratified M&K CPAs, PLLC as the independent registered public accounting firm for the fiscal year ended December 31, 2026, with 12,133,305 votes for, 48,079 against, and 1,482,721 abstentions.
What is the voting power of Syra Health (SYRA) Class B common stock?
The Company reported 350,000 shares of Class B common stock outstanding at the meeting, with each Class B share entitled to 16.5 votes, giving these shares higher voting power than standard common stock.